Epigenetic modifications play a major role in its transcriptional activation of Rac1 in the pathogenesis of diabetic retinopathy, and since epigenetic modifications can also be reversed, targeting such modifications is another possible therapeutic option. This evidence concerns the gene RAC1 and diabetic retinopathy.